Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3020% below fair value
$7.46−0.74 (-9.02%)
Close on Nov 20, 2026Market cap $502.36MP/E –Yield –
Ginkgo Bioworks gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.44M | – |
| Q1 FY2026 | Mar 31, 2026 | $16.38M | – |
| Q2 FY2025 | Jun 30, 2025 | $33.75M | – |
| Q1 FY2025 | Mar 31, 2025 | $34.14M | – |
See a number that looks wrong?